Aroa Biosurgery (ASX:ARX) Loans Receivable: A$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ARX Aroa Biosurgery Ltd ASX:ARX
60 GF Score
Price A$0.57
GF Value A$0.81
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery Loans Receivable?

Aroa Biosurgery ASX:ARX +0.89% 60 Loans Receivable is A$0.00 Mil as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 60/100 and a GF Value™ of A$0.81 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Aroa Biosurgery's Loans Receivable for the quarter that ended in Mar. 2026 was A$0.00 Mil.

Aroa Biosurgery Loans Receivable Related Terms

Aroa Biosurgery Loans Receivable Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Loans Receivable Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ARX
60GF Score
Aroa Biosurgery Ltd ASX:ARX
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of A$0.00 Mil mean?
Aroa Biosurgery (ASX:ARX) has a Loans Receivable of A$0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Loans Receivable too high?
Aroa Biosurgery's current Loans Receivable is A$0.00 Mil. Overall, Aroa Biosurgery has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Loans Receivable compare to ABT and SYK?
Aroa Biosurgery's Loans Receivable of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Devices & Instruments company?
A good Loans Receivable depends on the Medical Devices & Instruments industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Loans Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.81, compared to a current price of A$0.57 — trading 30.2% below its estimated fair value. The current Loans Receivable is A$0.00 Mil. Aroa Biosurgery's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Loans Receivable is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.57 is trading 30.2% below its estimated GF Value™ of A$0.81. GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.

Key valuation signals for ASX:ARX:

  • Loans Receivable: A$0.00 Mil
  • GF Value™: A$0.81 vs. price of A$0.57 (30.2% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
60GF Score

Get the complete analysis for ASX:ARX

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.57
Price
A$0.81
GF Value